Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Codex DNA	Harvard Bioscience	EyePoint Pharmaceuticals	Accelerate Diagnostics	Fluidigm
Symbol	NASDAQ:DNAY	NASDAQ:HBIO	NASDAQ:EYPT	NASDAQ:AXDX	NASDAQ:FLDM
Price Information
Current Price	$6.41	$6.64	$14.54	$4.77	$4.25
50-Day Moving Average	$9.45	$7.25	$13.22	$5.83	$5.11
52-Week Low	$6.22	$3.83	$4.00	$4.71	$3.71
52-Week High	$25.70	$8.75	$21.50	$15.60	$7.51
MarketRank™
Overall Score	1.8	2.4	2.3	2.7	2.0
Analysis Score	3.5	3.5	3.5	3.5	3.5
Community Score	4.7	4.9	4.8	4.5	5.0
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	1.7	3.3	5.0	1.7
Earnings & Valuation Score	0.0	1.9	0.0	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$23.19	$9.00	$22.38	$9.00	$7.00
% Upside from Price Target	261.78% upside	35.54% upside	53.89% upside	88.68% upside	64.71% upside
Trade Information
Market Cap	$187.86 million	$270.99 million	$492.82 million	$293.35 million	$325.07 million
Beta	N/A	1.77	1.13	1.79	1.22
Average Volume	116,844	208,245	374,490	349,223	1,373,403
Sales & Book Value
Annual Revenue	N/A	$102.10 million	$34.44 million	$11.16 million	$138.14 million
Price / Sales	N/A	2.65	14.31	26.29	2.35
Cashflow	N/A	$0.31 per share	N/A	N/A	N/A
Price / Cash	N/A	21.73	N/A	N/A	N/A
Book Value	$3.51 per share	$1.88 per share	$2.74 per share	($0.65) per share	$1.30 per share
Price / Book	N/A	3.53	5.31	-7.34	3.27
Profitability
Net Income	N/A	$-7.81 million	$-45.39 million	$-78.21 million	$-53.02 million
EPS	N/A	($0.05)	($2.50)	($1.25)	($0.90)
Trailing P/E Ratio	0.00	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	22.13	N/A	N/A	∞
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	-1.60%	-167.42%	-639.62%	-49.54%
Return on Equity (ROE)	N/A	9.59%	-64.16%	N/A	-43.70%
Return on Assets (ROA)	N/A	4.82%	-34.22%	-81.72%	-17.12%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.13	0.56	0.39	N/A	0.64
Current Ratio	14.93	2.37	7.11	9.52	1.55
Quick Ratio	14.72	1.26	6.88	8.23	1.04
Ownership Information
Institutional Ownership Percentage	55.18%	68.92%	74.10%	67.27%	75.63%
Insider Ownership Percentage	N/A	5.40%	26.74%	45.30%	2.90%
Miscellaneous
Employees	101	444	100	224	627
Shares Outstanding	29.31 million	40.81 million	33.89 million	61.50 million	76.49 million
Next Earnings Date	2/8/2022 (Estimated)	3/9/2022 (Estimated)	3/3/2022 (Estimated)	2/22/2022 (Estimated)	2/9/2022 (Estimated)
Optionable	Not Optionable	Optionable	Optionable	Optionable	Optionable

Source	Headline
	Analysts Provide Insight On How High Fluidigm Corporation (FLDM) Can Go stocksregister.com - December 4 at 9:05 AM
	RT-PCR Test Market is Booming Worldwide with Bioer, Abbott Laboratories, Biosynex, Thermo Fisher Scientific – UK Parents Lounge - UK Parents Lounge ukparentslounge.com - December 3 at 2:27 PM
	Fluidigm (NASDAQ:FLDM) vs. Olink Holding AB (publ) (NASDAQ:OLK) Critical Survey americanbankingnews.com - November 29 at 3:14 PM
	Global Microfluidics Market Trends and Forecasts to 2026: Shifting Trend Towards E-Health Diagnostics With the Integration of Microfluidics-Based POC - ACROFAN USA us.acrofan.com - November 26 at 1:17 PM
	Chip-based Digital PCR Systems Market analysis with Leading Key Players and Regional Analysis 2026 - Northwest Diamond Notes nwdiamondnotes.com - November 26 at 8:16 AM
	Global Microfluidics Market Trends and Forecasts to 2026: Shifting Trend Towards E-Health Diagnostics With the Integration of Microfluidics-Based POC Devices, Epidermal Electronics and IoT - ResearchAndMarkets.com - Business Wire businesswire.com - November 26 at 8:16 AM
	RT-PCR Kits Market 2020 (COVID-19 Impact Analysis Included) Opportunities, Regional Overview, Top Le - PharmiWeb.com pharmiweb.com - November 25 at 9:38 AM
	10x Genomics Stock: Bull vs. Bear - Motley Fool fool.com - November 24 at 12:51 PM
	Worldwide Single Cell Genomics Industry Report to 2026 - Technology Maturity & Convergence are Driving Growth - WFMZ Allentown wfmz.com - November 24 at 7:36 AM
	Multi-PCR Detection Market is Anticipated to Witness Outstanding Growth Over the forecast period 2021-2027 Alo - openPR openpr.com - November 23 at 12:56 PM
	Insights on the Single Cell Genomics Global Market to 2026 - GlobeNewswire globenewswire.com - November 23 at 12:56 PM
	Global Microfluidic Chips Market 2021-2027 Regional Analysis, Types, and Applications - Top Key Players as Agilent, Fluidigm Corporation, Micralyne, Inc - Big News Network bignewsnetwork.com - November 23 at 7:55 AM
	Worldwide Sequencing Reagents Industry to 2028 - Focus on Oncology, Clinical Investigation, Agri Genomics & Forensics and Reproductive Health - Yahoo Finance finance.yahoo.com - November 22 at 7:59 AM
	Fluidigm Corporation’s (FLDM) Outlook: Recollecting The Past For Future Insights stocksregister.com - November 22 at 1:00 AM
	People in the News: New Appointments at Rebus Biosystems, Jumpcode Genomics, Epigenomics, More - GenomeWeb genomeweb.com - November 19 at 3:00 PM
	Insights on the Sequencing Reagents Global Market to 2028 - Funding by Manufacturers and Government in Genomics Presents Opportunities - Yahoo Finance finance.yahoo.com - November 19 at 9:30 AM
	Worldwide Polymerase Chain Reaction Industry to 2026 - Featuring BioMerieux, Fluidigm and Promega Among Others - PRNewswire prnewswire.com - November 19 at 9:30 AM
	Worldwide Polymerase Chain Reaction Industry to 2026 - Featuring BioMerieux, Fluidigm and Promega Among Others - Yahoo Finance finance.yahoo.com - November 18 at 9:16 AM
	Single Cell Analysis Market to Exhibit Positive and Steady Growth, Players – Agilent Technologies, Fluidigm Corporation. – Energy Siren - Energy Siren energysiren.co.ke - November 17 at 9:03 AM
	Single-Cell Analysis Market Size, Growth (2021-2028) \| Top Companies – Merck, Thermo Fisher Scientific, Becton Dickinson, Beckman Coulter, Bio-Rad Laboratories, Qiagen, Illumina, GE Healthcare, Agilent Technologies, Fluidigm Corporation, – Energy Sire - Energy Siren energysiren.co.ke - November 17 at 4:02 AM
	Sample Preparation Products for Next Generation Sequencing Market: Size, Growth, Forecast, Business Outlook 2021-2027 \| 10X Genomics, Pacific Biosciences, Fluidigm, Agilent Technologies, Oxford Nanâ€¦. – Energy Siren - Energy Siren energysiren.co.ke - November 17 at 4:02 AM
	Library Preparation and Target Enrichment for Next Generation Sequencing Product Market: Size, Growth, Forecast, Business Outlook 2021-2027 \| Fluidigm, Roche, Illumina, Thermo Fisher Scientific, Agâ€¦. – Energy Siren - Energy Siren energysiren.co.ke - November 17 at 4:02 AM
	Digital PCR-dPCR Market Size, Growth (2021-2028) \| Top Companies – Fluidigm, Bio-rad, Thermo Fisher, RainDance Technologies, – Energy Siren - Energy Siren energysiren.co.ke - November 17 at 4:02 AM
	Polymerase Chain Reaction (PCR) Technologies Market Rugged Expansion Foreseen by 2026 – Fluidigm Corporation, Bio-Rad Laboratories, Inc., Qiagen NV, LGC Limited, etc – Energy Siren - Energy Siren energysiren.co.ke - November 17 at 4:02 AM
	MEMS (Biosensors and Nanosensors) Market Size, Growth (2021-2028) \| Top Companies – Abbott Laboratories, Agilent Technologies, Bruker Corp., Robert Bosch Gmbh, Thermo Fisher Scientific Inc., Panasonic Corp., Bio-Rad Laboratories, Cepheid Therape - Energy Siren energysiren.co.ke - November 16 at 5:16 PM

Date	Company	Brokerage	Action
11/15/2021	EyePoint Pharmaceuticals	Cowen	Boost Price Target
11/15/2021	EyePoint Pharmaceuticals	HC Wainwright	Reiterated Rating
10/15/2021	Codex DNA	Cowen	Initiated Coverage
10/13/2021	EyePoint Pharmaceuticals	HC Wainwright	Reiterated Rating
7/21/2021	EyePoint Pharmaceuticals	HC Wainwright	Reiterated Rating
7/13/2021	Codex DNA	Jefferies Financial Group	Initiated Coverage
7/13/2021	Codex DNA	Cowen	Initiated Coverage
7/13/2021	Codex DNA	KeyCorp	Initiated Coverage
7/9/2021	EyePoint Pharmaceuticals	HC Wainwright	Reiterated Rating
7/2/2021	EyePoint Pharmaceuticals	HC Wainwright	Reiterated Rating
5/26/2021	EyePoint Pharmaceuticals	HC Wainwright	Reiterated Rating
5/12/2021	Fluidigm	Piper Sandler	Lower Price Target
5/10/2021	Accelerate Diagnostics	Piper Sandler	Lower Price Target
5/6/2021	EyePoint Pharmaceuticals	HC Wainwright	Lower Price Target
3/10/2021	Harvard Bioscience	KeyCorp	Boost Price Target
3/1/2021	EyePoint Pharmaceuticals	Cowen	Initiated Coverage
2/11/2021	Fluidigm	Piper Sandler	Lower Price Target
1/29/2021	EyePoint Pharmaceuticals	HC Wainwright	Reiterated Rating
1/27/2021	EyePoint Pharmaceuticals	Cantor Fitzgerald	Initiated Coverage
1/12/2021	EyePoint Pharmaceuticals	B. Riley	Boost Price Target
1/7/2021	Harvard Bioscience	Benchmark	Upgrade
12/9/2020	Harvard Bioscience	Northland Securities	Initiated Coverage
11/9/2020	Harvard Bioscience	KeyCorp	Initiated Coverage
11/6/2020	Accelerate Diagnostics	Piper Sandler	Lower Price Target
10/9/2020	EyePoint Pharmaceuticals	HC Wainwright	Upgrade
10/7/2020	Accelerate Diagnostics	BTIG Research	Initiated Coverage
8/27/2020	Fluidigm	UBS Group	Boost Price Target
8/10/2020	Accelerate Diagnostics	Piper Sandler	Boost Price Target
8/10/2020	Fluidigm	UBS Group	Boost Price Target
8/7/2020	Accelerate Diagnostics	Craig Hallum	Upgrade
8/7/2020	Fluidigm	Piper Sandler	Boost Price Target
8/6/2020	EyePoint Pharmaceuticals	HC Wainwright	Reiterated Rating
7/9/2020	Fluidigm	Piper Sandler	Reiterated Rating
7/9/2020	Fluidigm	BTIG Research	Reiterated Rating
5/11/2020	Accelerate Diagnostics	Piper Sandler	Lower Price Target
4/6/2020	EyePoint Pharmaceuticals	B. Riley	Downgrade
4/2/2020	EyePoint Pharmaceuticals	HC Wainwright	Reiterated Rating
3/3/2020	EyePoint Pharmaceuticals	HC Wainwright	Reiterated Rating
2/27/2020	Harvard Bioscience	Benchmark	Boost Price Target
2/11/2020	Fluidigm	Piper Sandler	Lower Price Target
2/4/2020	EyePoint Pharmaceuticals	HC Wainwright	Reiterated Rating
1/24/2020	EyePoint Pharmaceuticals	HC Wainwright	Reiterated Rating
1/14/2020	Accelerate Diagnostics	Piper Sandler	Boost Price Target
12/9/2019	Harvard Bioscience	Benchmark	Downgrade
11/11/2019	EyePoint Pharmaceuticals	HC Wainwright	Downgrade
11/6/2019	Fluidigm	Janney Montgomery Scott	Downgrade
11/5/2019	EyePoint Pharmaceuticals	HC Wainwright	Reiterated Rating
11/4/2019	EyePoint Pharmaceuticals	Laidlaw	Initiated Coverage
10/18/2019	Fluidigm	UBS Group	Upgrade
9/27/2019	Accelerate Diagnostics	JPMorgan Chase & Co.	Downgrade
9/25/2019	EyePoint Pharmaceuticals	HC Wainwright	Reiterated Rating
9/24/2019	EyePoint Pharmaceuticals	B. Riley	Lower Price Target
9/12/2019	EyePoint Pharmaceuticals	Guggenheim	Initiated Coverage
8/9/2019	Accelerate Diagnostics	Piper Jaffray Companies	Lower Price Target
7/19/2019	Harvard Bioscience	Benchmark	Reiterated Rating
7/8/2019	Harvard Bioscience	Janney Montgomery Scott	Downgrade
5/12/2019	Accelerate Diagnostics	BTIG Research	Reiterated Rating
5/3/2019	Fluidigm	Piper Jaffray Companies	Boost Price Target
3/15/2019	Fluidigm	UBS Group	Initiated Coverage
3/13/2019	Fluidigm	BTIG Research	Initiated Coverage
3/13/2019	Fluidigm	Piper Jaffray Companies	Boost Price Target
2/20/2019	Accelerate Diagnostics	Piper Jaffray Companies	Boost Price Target
2/18/2019	Harvard Bioscience	Janney Montgomery Scott	Reiterated Rating
1/11/2019	Accelerate Diagnostics	Piper Jaffray Companies	Lower Price Target
1/3/2019	Fluidigm	Janney Montgomery Scott	Upgrade

(Data available from 12/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources